Compare SCHL & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SCHL | ALT |
|---|---|---|
| Founded | 1920 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Books | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 672.6M | 573.8M |
| IPO Year | 1995 | 2005 |
| Metric | SCHL | ALT |
|---|---|---|
| Price | $36.13 | $2.78 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $17.11 |
| AVG Volume (30 Days) | 381.9K | ★ 3.1M |
| Earning Date | 09-24-2026 | 11-05-2026 |
| Dividend Yield | ★ 2.84% | N/A |
| EPS Growth | ★ 3442.86 | 25.37 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,487,100,000.00 | $41,000.00 |
| Revenue This Year | $2.14 | N/A |
| Revenue Next Year | $3.42 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 105.00 |
| 52 Week Low | $26.38 | $2.56 |
| 52 Week High | $48.07 | $6.44 |
| Indicator | SCHL | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 43.84 | 34.73 |
| Support Level | $32.81 | $2.80 |
| Resistance Level | $35.89 | $3.35 |
| Average True Range (ATR) | 1.14 | 0.12 |
| MACD | 0.25 | -0.06 |
| Stochastic Oscillator | 75.14 | 3.28 |
Scholastic Corp is a publisher and distributor of children's books, a provider of print and digital instructional materials for grades pre-kindergarten (pre-K) to grade 12 and a producer of entertaining literary and educational children's media. The company creates quality print, digital and audio books, learning materials and programs, classroom magazines and other products that, in combination, offer children, families and educators engaging and comprehensive solutions to support children's learning and reading both at home and at school. It categorizes its businesses into four reportable segments: Children's Book Publishing and Distribution; Education; Entertainment; and International. It derives the majority of revenue from Children's Book Publishing and Distribution segment.
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.